Comparative Pharmacology
Head-to-head clinical analysis: ARISTOCORT versus DEXAMETHASONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTOCORT versus DEXAMETHASONE.
ARISTOCORT vs DEXAMETHASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; modulates gene expression and immune cell activity.
Agonist at glucocorticoid receptors, leading to altered gene expression and suppression of inflammatory mediators.
Intramuscular: 40-80 mg every 2-4 weeks; Intra-articular: 5-40 mg depending on joint size; Intralesional: 2.5-25 mg; Oral: 4-12 mg/day divided every 6-12 hours.
0.5-24 mg/day oral, IV, IM in 2-4 divided doses; anti-inflammatory: 0.75-9 mg/day; multiple myeloma: 40 mg oral/IV once daily on days 1-4, 9-12, 17-20 every 28 days.
None Documented
None Documented
Clinical Note
moderateDexamethasone + Digoxin
"Dexamethasone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDexamethasone + Digitoxin
"Dexamethasone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDexamethasone + Deslanoside
"Dexamethasone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDexamethasone + Acetyldigitoxin
"Dexamethasone may decrease the cardiotoxic activities of Acetyldigitoxin."
Plasma: 1-2 hours (triamcinolone); tissue half-life 18-36 hours due to receptor binding and slow release from tissues.
Terminal elimination half-life 3-4 hours; clinically, duration of HPA suppression may exceed 24 hours due to prolonged receptor binding.
Renal (primarily as inactive metabolites); <5% unchanged. Biliary/fecal elimination minor.
Primarily renal (65-80% as unchanged drug); minor biliary/fecal (<10%).
Category C
Category D/X
Corticosteroid
Corticosteroid